GlassScriptPhysician profile
Firras S Garada
NPI 1073008371
$13,881.72
in general payments reported to CMS, 2019-2025
30 companies · $2,164 in 2025
The $2,164 reported for 2025 was more than what 85% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $321 · 2021: $2,979 · 2022: $3,837 · 2023: $2,753 · 2024: $550 · 2025: $2,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,653 · Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,652.90 |
| Food and Beverage | $1,814.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $2,887.25 | 2022 | |
| Pinnacle, INC | $2,098.93 | 2019-2021 | |
| Mimedx Group, INC. | $1,854.47 | 2025 | |
| Stryker Corporation | $1,450.16 | 2019-2024 | Actishield, Citrefix, Anchorage |
| Medical Device Business Services, INC. | $1,316.57 | 2023 | |
| Treace Medical Concepts, INC. | $1,198.80 | 2022-2025 | |
| Paragon 28, INC. | $838.90 | 2021-2023 | Portfolio |
| Organogenesis INC. | $643.41 | 2021-2025 | Affinity |
| Kci USA, INC. | $185.52 | 2019-2020 | |
| Horizon Therapeutics Plc | $177.39 | 2022-2023 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $175.37 | 2022-2025 | Nuzyra |
| Depuy Synthes Sales INC. | $155.81 | 2024-2025 | Na |
| Integra Lifesciences Corporation | $136.51 | 2019-2020 | |
| Smith+Nephew, INC. | $111.81 | 2020-2025 | Grafix Pl, Stravix, Pico |
| Osteomed LLC | $97.45 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $94.51 | 2021 | |
| Terumo Medical Corporation | $78.77 | 2021 | |
| Axogen | $78.26 | 2020 | |
| Misonix INC | $50.00 | 2021 | |
| Wright Medical Technology, INC. | $37.00 | 2019 | |
| Acera Surgical, INC. | $35.65 | 2019 | |
| Orthofix Medical, INC. | $27.81 | 2022-2023 | Physio-Stim |
| Amgen INC. | $26.37 | 2024 | Krystexxa |
| Kerecis Limited | $26.02 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Tei Medical INC. | $20.88 | 2019 | |
| Novastep INC. | $19.11 | 2022 | |
| Surgenex LLC | $17.53 | 2025 | Renograft, Ardeograft, Surgraft |
| Convatec INC. | $14.66 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $13.68 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firras Garada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.